Cencora, Inc.

Valuation Analysis

About the Company

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcar

Cencora, Inc. Stock at a Glance

Cencora, Inc. (COR) is currently trading at $281.67 with a market capitalization of $54.8B. The trailing P/E ratio stands at 21.6x, with a forward P/E of 14.24x. The 52-week range spans from $244.82 to $377.54; the current price is 25.4% below the yearly high. Year-over-year revenue growth stands at +3.8%. The net profit margin stands at 0.78%.

💰 Dividend

Cencora, Inc. pays an annual dividend of $2.40 per share, representing a yield of 0.85%. The payout ratio stands at 17.62%.

📊 Analyst Rating

12 analysts rate Cencora, Inc. (COR) on consensus: Buy. The average price target is $350.58, implying +24.47% from the current price. Analyst price targets range from $280.00 to $412.00.

Cencora, Inc.: The Investment Case in Detail

Cencora, Inc. (COR) operates in the Healthcare — specifically Medical Distribution — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 128.3% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Return on equity of 107.13% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Wall Street consensus sits at Buy with an average price target implying roughly 24.47% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Revenue growth has slowed to just 3.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy. With a net margin of just 0.78%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. The debt-to-equity ratio of 420.99% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valuation in Context

With a PEG ratio of 0.6, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 14.24x is meaningfully below the trailing 21.6x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 24.47% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Cencora, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.